Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates
Information source: Ann & Robert H Lurie Children's Hospital of Chicago
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Postoperative Pain
Intervention: Bupivacaine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Ann & Robert H Lurie Children's Hospital of Chicago Official(s) and/or principal investigator(s):
Santhanam Suresh, MD, Principal Investigator, Affiliation: Ann & Robert H Lurie Children's Hospital of Chicago
Summary
This study is being done to try to learn more about how a child's body breaks down
bupivacaine, a local anesthetic medication that is being used for pain control. This study
will provide information about how much medication gets into the bloodstream and how long it
remains in the blood. Newborns and young infants often process drugs in their body in a
different way than older children. This study will help the investigators determine how
bupivacaine is broken down in the body of infants.
Clinical Details
Official title: Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Primary outcome: Pharmacokinetics of Bupivacaine
Secondary outcome: Pharmacodynamics of Bupivacaine
Detailed description:
A transverse abdominal plane (TAP_ block will be performed by one of the investigators who
is adept in using ultrasound guidance after induction of general anesthesia. The dose of
bupivacaine administered will be based on the weight of the patient. This dose is consistent
with routine levels of local anesthetic used for peripheral nerve blocks and is lower than
toxic levels so there will be no additional change in renal or liver function. Whole blood
samples will be collected on a piece of filter paper from either an arterial, central,
peripheral line or heel stick. The extracts from dried blood samples (DBS; calculated volume
20 µL) collected on filter paper will be analyzed using an LC-MS/MS system in combination
with online extraction (LC/LC-MS/MS). Blood samples will be obtained at 0, 5, 15, 30, 60,
120 minutes, 4, 24, 48 hours. If obtained from a heel stick, these samples will be obtained
at time of glucose sampling or a clinical indication. Subjects will be considered evaluable
if they have 5 samples. All sampling for the study will be based on concurrent sampling so
there will be no additional blood draws.
Pain will be assessed by the bedside nurse or study research assistant using the Neonatal
Infant Pain Scale (NIPS). As part of the standard of care in this institution, nurses will
have the opportunity to administer additional pain medications including but not limited to
intravenous fentanyl or morphine. This will be done as per standing orders if the neonate
meets criteria for additional analgesia, in other words, if there is an increase in pain as
indicated by the NIPS pain scores. NIPS score will be recorded prior to each blood draw and
every 8 hours while the subject is enrolled in the study. The NIPS will be the primary
clinical outcome measure for this study. Blood pressure and heart rate will also be recorded
as a physiologic correlate for drug level at these times.
Eligibility
Minimum age: N/A.
Maximum age: 28 Days.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Neonates under 28 days of age undergoing any abdominal surgery including laparotomy,
colostomy placement. In addition neonates who have procedures performed using
laparoscopic as well as open techniques will be included
- Written informed consent from parent or guardian
Exclusion Criteria:
- Neonates with significant cardiovascular disease (any child with any congenital heart
disease will be excluded from the study)
- Neonates with significant liver disease (any neonate with ALT/AST elevated 30% above
normal values as determined by the lab at Lurie Children's at the time of testing)
- Neonates under 1. 65 kg
Locations and Contacts
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois 60611, United States
Additional Information
Related publications: Abdel-Rahman SM, Jacobs RF, Massarella J, Kauffman RE, Bradley JS, Kimko HC, Kearns GL, Shalayda K, Curtin C, Maldonado SD, Blumer JL. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother. 2007 Aug;51(8):2668-73. Epub 2007 May 21. Bielsky A, Efrat R, Suresh S. Postoperative analgesia in neonates after major abdominal surgery: 'TAP' our way to success! Paediatr Anaesth. 2009 May;19(5):541-2. doi: 10.1111/j.1460-9592.2009.02988.x. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit. 2005 Dec;27(6):770-8. Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, Carlson L, Benet LZ. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation. 2005 Jul 15;80(1):13-7. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GI. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl. 2000 Oct 1;748(1):41-53. Lawrence J, Alcock D, McGrath P, Kay J, MacMurray SB, Dulberg C. The development of a tool to assess neonatal pain. Neonatal Netw. 1993 Sep;12(6):59-66.
Starting date: July 2010
Last updated: March 19, 2013
|
